Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol 2015 Nov;90(11):967-9
Date
07/24/2015Pubmed ID
26202978Pubmed Central ID
PMC7055503DOI
10.1002/ajh.24125Scopus ID
2-s2.0-84944525401 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Little is known about outcomes of patients with chronic lymphocytic leukemia (CLL) with del(17p13.1) karyotype at diagnosis. We reviewed 114 de novo del(17p13.1) CLL patients seen at our institution. Using proportional hazards models to identify pretreatment clinical variables significantly associated with treatment-free survival (TFS) and overall survival (OS), we developed a simplified risk score for de novo del(17p13.1) CLL patients to predict TFS and OS based on these variables. These scores, particularly the very highest, can be utilized to identify high-risk patients for expedient enrollment on clinical trials. Our data support careful observation for low-risk patients, potentially preventing unnecessary use of aggressive therapies.
Author List
Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JCAuthor
Samantha M. Jaglowski MD, MPH Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Antineoplastic Agents
Base Sequence
Chromosomes, Human, Pair 17
Female
Humans
Karyotype
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Molecular Sequence Data
Prognosis
Proportional Hazards Models
Retrospective Studies
Risk
Sequence Deletion
Survival Analysis
